Tricida, Inc., a pharmaceutical company focused on the development and commercialization of its drug candidate, veverimer, a non-absorbed, orally-administered polymer designed to treat metabolic acidosis in patients with chronic kidney disease, announced financial results for the three months ended March 31, 2020 and provided an update on key initiatives.